SecBot SecBot
SECBOTREPLAY Home › Report › MLYS

MLYS · Mineralys Therapeutics repurchased its royalty obligation to Tanabe for…

Mineralys Therapeutics, Inc. · PRESS-RELEASE filed Jun 3, 2026 at 06:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 3, 2026 at 06:00 ET

Mineralys Therapeutics repurchased its royalty obligation to Tanabe for $200M upfront (up to $100M in milestones), secured a $500M debt facility from Pharmakon (first tranche $100M), and priced a $150M common stock offering. The transactions eliminate future royalty payments, strengthen the balance sheet, and provide capital to support lorundrostat's commercialization ahead of an NDA review.

  • Repurchased all future royalty payments to Tanabe for $200M upfront plus up to $100M in commercial milestones
  • Entered $500M senior secured term loan facility with Pharmakon Advisors; first tranche of $100M funded at closing
  • Priced $150M common stock offering
  • Tanabe to assign intellectual property rights for lorundrostat to Mineralys

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access